[go: up one dir, main page]

MX2015015015A - Metodo para diagnosticar cancer. - Google Patents

Metodo para diagnosticar cancer.

Info

Publication number
MX2015015015A
MX2015015015A MX2015015015A MX2015015015A MX2015015015A MX 2015015015 A MX2015015015 A MX 2015015015A MX 2015015015 A MX2015015015 A MX 2015015015A MX 2015015015 A MX2015015015 A MX 2015015015A MX 2015015015 A MX2015015015 A MX 2015015015A
Authority
MX
Mexico
Prior art keywords
diagnosing cancer
cancer
cd95l
expression
diagnosing
Prior art date
Application number
MX2015015015A
Other languages
English (en)
Other versions
MX363679B (es
Inventor
Christian Gieffers
Harald Fricke
Jaromir Sykora
Original Assignee
Apogenix Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apogenix Gmbh filed Critical Apogenix Gmbh
Publication of MX2015015015A publication Critical patent/MX2015015015A/es
Publication of MX363679B publication Critical patent/MX363679B/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153 or CD154
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La presente invención se relaciona con un método para diagnosticar una enfermedad por cáncer, que comprende (a) determinar la expresión de CD95L en una muestra de cáncer, y (b) clasificar la enfermedad de cáncer de acuerdo con el nivel de expresión de CD95L.
MX2015015015A 2013-04-29 2014-04-29 Metodo para diagnosticar cancer. MX363679B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13165784 2013-04-29
PCT/EP2014/058746 WO2014177576A1 (en) 2013-04-29 2014-04-29 Method of diagnosing cancer

Publications (2)

Publication Number Publication Date
MX2015015015A true MX2015015015A (es) 2016-07-21
MX363679B MX363679B (es) 2019-03-29

Family

ID=48190325

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015015015A MX363679B (es) 2013-04-29 2014-04-29 Metodo para diagnosticar cancer.

Country Status (9)

Country Link
US (1) US20160103132A1 (es)
EP (1) EP2992330B1 (es)
JP (1) JP6556121B2 (es)
CN (1) CN105393121B (es)
AU (1) AU2014261505B2 (es)
BR (1) BR112015027249A2 (es)
CA (1) CA2910332A1 (es)
MX (1) MX363679B (es)
WO (1) WO2014177576A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ703546A (en) * 2012-07-18 2018-03-23 Apogenix Ag Composition comprising a mixture of cd95-fc isoforms
EP3137909B1 (en) 2014-04-29 2018-06-06 Apogenix AG Diagnostic anti-cd95l antibody
EP3076179A1 (en) * 2015-03-30 2016-10-05 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Diagnosis and treatment of low grade gliomas
WO2017009429A1 (en) * 2015-07-14 2017-01-19 Apogenix Ag Method of predicting the responsiveness of a cancer disease to treatment
JP2024544076A (ja) * 2021-12-01 2024-11-27 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） 抗ｃｄ９５ｌモノクローナル中和抗体

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2377247A1 (en) * 1999-07-16 2001-01-25 Maxim Pharmaceuticals, Inc. Activation and protection of cytotoxic lymphocytes using a reactive oxygen metabolite inhibitor
EP1417353A4 (en) * 2001-07-20 2005-08-03 Univ Texas METHODS AND COMPOSITIONS ASSOCIATED WITH HPV ASSOCIATED PENCILS AND CANNULAR WELLS, INCLUDING CIN
WO2003027242A2 (en) * 2001-09-24 2003-04-03 Duke University Fas ligand
JP2005520523A (ja) * 2002-03-21 2005-07-14 イーライ・リリー・アンド・カンパニー アンタゴニスト的抗ｈＦａｓリガントヒト抗体およびそのフラグメント
ES2393762T3 (es) * 2006-11-10 2012-12-27 Alphaptose Gmbh Procedimientos y composiciones para detectar miméticos de ligandos de receptores
ES2420582T3 (es) * 2006-12-28 2013-08-26 Deutsches Krebsforschungszentrum, Stiftung Des Öffentlichen Rechts La neutralización de la actividad de CD95 bloquea la invasión de células de glioblastoma in vivo
CN102016552A (zh) * 2008-03-05 2011-04-13 神谷来克斯公司 用于分子的高灵敏性检测的方法和组合物
EP2456468A1 (en) * 2009-07-21 2012-05-30 Queen Mary and Westfield College Fas (apo-1, cd95) targeted platforms for intracellular drug delivery
KR20140067001A (ko) * 2011-08-08 2014-06-03 카리스 라이프 사이언스 룩셈부르크 홀딩스, 에스.에이.알.엘. 생물지표 조성물 및 방법
NZ703546A (en) * 2012-07-18 2018-03-23 Apogenix Ag Composition comprising a mixture of cd95-fc isoforms

Also Published As

Publication number Publication date
EP2992330B1 (en) 2018-04-18
JP2016524694A (ja) 2016-08-18
AU2014261505B2 (en) 2019-04-18
EP2992330A1 (en) 2016-03-09
CN105393121A (zh) 2016-03-09
US20160103132A1 (en) 2016-04-14
MX363679B (es) 2019-03-29
JP6556121B2 (ja) 2019-08-07
CN105393121B (zh) 2018-04-24
BR112015027249A2 (pt) 2017-09-26
AU2014261505A1 (en) 2015-11-12
WO2014177576A1 (en) 2014-11-06
CA2910332A1 (en) 2014-11-06

Similar Documents

Publication Publication Date Title
AR090973A1 (es) Anticuerpos utiles para el diagnostico del cancer
EA201590027A1 (ru) Способы детекции заболеваний или состояний
EP3064940A4 (en) Salivary biomarker for cancer, method and device for assaying same, and method for determining salivary biomarker for cancer
MX340453B (es) Biomarcadores para cancer de pulmon.
CO7151527A2 (es) Anticuerpos anti-cd79 b e inmunoconjugados
MX2015017331A (es) Anticuerpos anti fc similar a receptor 5 (fcrh5).
SG11201504874QA (en) Sample analysis for mass cytometry
NZ629555A (en) Monocyte biomarkers for cancer detection
MX365061B (es) Biomarcadores relacionados a la funcion renal y metodos para usar los mismos.
MX2016004865A (es) Metodo y dispositivo para analizar relacion social.
MA38500A1 (fr) Systèmes et procédés pour analyser une nourriture pour animal
EP3011055A4 (en) Classification system, methods and kit for classifying. predicting and treating breast cancer
EP3176268A4 (en) Novel biomarker for predicting sensitivity to egfr-targeting agent, and use thereof
MX2015015452A (es) Metodo y sistema para evaluar una condicion de salud.
MX358474B (es) Biomarcadores salivales específicos para detección de riesgo, diagnóstico temprano, pronóstico y vigilancia de las enfermedades de alzheimer y de parkinson.
MX353954B (es) Aptameros y metodos de diagnostico para detectar el receptor del factor de crecimiento epidermal (egf).
NZ716643A (en) Methods for predicting the risk of having a cardiovascular event and for monitoring the treatment of a cardiovascular event
EA201591742A1 (ru) Способ улучшения диагностики заболеваний с использованием измеряемых аналитов
MX2016006165A (es) Composiciones y metodos para valorar la funcion intestinal.
MX2015015015A (es) Metodo para diagnosticar cancer.
EP3122906A4 (en) Hpv16 antibodies as diagnostic and prognostic biomarkers in pre-invasive and invasive disease
WO2013124738A3 (en) Methods and biomarkers for detection and prognosis of cervical cancer
MX2019002818A (es) Metodos para detectar anticuerpos neutralizantes anti-leptina.
IN2015DN01646A (es)
AU2012371260A8 (en) Predicitive biomarker for cancer treatment with ADCC enhanced antibodies